Futibatinib for advanced bile duct cancer with FGFR2 changes
Part of Cancer clinical trials.
This trial tests futibatinib, a targeted pill, in people with advanced (unresectable) or metastatic bile duct cancer that has an FGFR2 fusion or rearrangement. It may help shrink tumors after standard chemotherapy has stopped working.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Have bile duct cancer that cannot be fully removed or has spread (intrahepatic or extrahepatic).
- Your tumor test must show an FGFR2 gene fusion or rearrangement.
- You must have already tried at least one gemcitabine + platinum chemotherapy treatment.
- Your scans must show the cancer got worse after the most recent treatment.
- You must have measurable tumors on imaging and be able to do normal daily activities (performance status 0 or 1).
- Your body organs (blood, liver, kidneys) must be strong enough for treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs (pemigatinib, atezolizumab, and bevacizumab) for people with advanced bile duct cancer that has a specific genetic change called FGFR2 fusion. The goal is to see if this combination can shrink or control the cancer when standard treatments have stopped working.
This trial tests a new targeted drug called TT-00420 (tinengotinib) against standard chemotherapy for people with a specific type of bile duct cancer that has a change in the FGFR2 gene. The drug is designed to target and block cancer cells with that gene change, possibly slowing the cancer's growth.
This trial tests a new targeted therapy, futibatinib, for people with advanced or unresectable bile duct cancer who have not had prior treatment for advanced disease. It aims to see if this drug can help shrink or control the cancer.
This trial tests whether matching targeted therapy to the genetic changes in your cancer can lower the chance of it coming back after surgery. You would first have your tumor tested for specific alterations, and if one is found, you may receive a drug that targets it.
This trial tests a new combination of drugs (futibatinib plus chemo-immunotherapy) for people with advanced colorectal cancer who have not had prior treatment. It aims to see if this combination can shrink tumors or slow their growth.
This study tests a combination of two drugs—pemigatinib (a targeted therapy) and a PD-1 inhibitor (an immunotherapy)—with or without chemotherapy, for people with advanced bile duct cancer that has an FGFR2 fusion or rearrangement. The goal is to see if this combination is more effective than standard treatment, and to find better ways to treat this type of cancer.
Hear when a new Advanced Cholangiocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.